There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d11749959e100">Background: Mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase
domain (TKD) are associated with response and resistance to targeted therapy. The
EGFR mutation status in patients with advanced oral and oropharyngeal squamous cell
carcinoma (OOSCC) was evaluated. A systematic literature review was undertaken to
summarize current evidence and estimate the overall prevalence of EGFR TKD mutations
in patients with head and neck squamous cell carcinoma (HNSCC). Materials and Methods:
Genomic DNA was extracted from formalin-fixed, paraffin-embedded tumor samples of
113 patients with OOSCC. Pyrosequencing was performed to investigate mutations in
EGFR exons 18 to 21. Medline databases were searched for relevant studies. Studies
reporting mutations in the EGFR TKD in HNSCC were eligible for inclusion in the systematic
review. Results: No mutations in the EGFR TKD were observed in 113 samples of OOSCC.
A total of 53 eligible studies were included in the systematic review. In total, from
the review, 117 patients harboring a total of 159 EGFR TKD mutations were reported
among 4122 patients with HNSCC. The overall prevalence of EGFR TKD mutations in HNSCC
was 2.8%. Conclusion: Large-scale studies are warranted to provide further evidence
regarding the mutation status of EGFR in patients with HNSCC.
</p>